



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



PRODUCT INFORMATION

Common Name	AiRuiKa;Carbarizumab;Carrizumab;HR-301210;HR301210;INCSHR-1210;INCSHR1210;SHR1210;HSR1210;HSR-1210
Conjugate	PE-conjugated
Synonyms	PD1;PD-1;CD279;SLEB2;hPD-1;hPD-I;hSLE1
Applications	Flow Cyt
Recommended Dilutions	Flow Cyt 1:100
Formulation & Reconstitution	Liquid□PBS with 0.05% Proclin300, 1% BSA
Host Species	N/A
IgG type	IgG4
Reactivity	Human
Target	PD-1
Uniprot ID	Q15116
Description	PE-conjugated Anti-PD-1(camrelizumab biosimilar) mAb
Delivery	Under Development
Storage & Shipping	Store at 2°C-8°C for 6 months
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

